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ORIGINAL ARTICLE
Patient-Reported Outcomes From a Two-Year
Head-to-Head Comparison of Subcutaneous
Abatacept and Adalimumab for Rheumatoid
Arthritis
ROY FLEISCHMANN,1 MICHAEL E. WEINBLATT,2 MICHAEL SCHIFF,3 DINESH KHANNA,4
MICHAEL A. MALDONADO,5 ANAGHA NADKARNI,5 AND DANIEL E. FURST6
Objective. To report 2-year patient-reported outcomes (PROs) from the head-to-head Abatacept versus Adalimumab
Comparison in Biologic-Naive RA Subjects with Background Methotrexate (MTX) (AMPLE) trial.
Methods. AMPLE was a phase IIIb, randomized, investigator-blinded trial. Biologic-naive patients with rheumatoid
arthritis (RA) and an inadequate response to MTX were randomized to subcutaneous (SC) abatacept (125 mg/week) or
adalimumab (40 mg every 2 weeks) with background MTX. PROs (pain, fatigue, ability to perform work, and ability
to perform daily activities) were compared up to year 2 for patients in each treatment group, as well as those who
achieved low disease activity at both years 1 and 2 (responders) and those who did not (nonresponders).
Results. A total of 646 patients were randomized and treated with SC abatacept (n 5 318) or adalimumab (n 5 328). Base-
line characteristics were balanced between the 2 treatment arms. Comparable improvements in PROs were observed in
the abatacept and adalimumab groups over 2 years, with both groups achieving clinically meaningful improvements in
PROs from baseline. At year 2, fatigue improved by 23.4 mm and 21.5 mm on a 100-mm visual analog scale with abatacept
and adalimumab, respectively. Clinical responders achieved greater improvements in PROs than nonresponders.
Conclusion. In biologic-naive patients with active RA, despite prior MTX, treatment with SC abatacept or adalimu-
mab with background MTX resulted in comparable improvements in PROs, which were highly correlated with
physician-reported clinical response end points.
INTRODUCTION
Rheumatoid arthritis (RA) can have a major impact on
patient-reported outcomes (PROs) that evaluate health,
quality of life, and treatment response from the perspec-
tive of the patient. PROs that are considered to have a par-
ticularly large impact on the quality of life of patients with
RA include pain, fatigue, the ability to perform work, and
the ability to perform daily activities (1).
The treat-to-target strategies employed in RA aim to
achieve significant improvements in clinical outcomes,
with the goal of remission, or if remission cannot be
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achieved, low disease activity. However, whether achieve-
ment of these goals is associated with meaningful improve-
ments in PROs remains unclear. It is, therefore, important
that PROs are evaluated in conjunction with clinical out-
comes, particularly when disease activity is assessed using
a measure that does not include a patient-reported compo-
nent. As both clinical outcomes and PROs are important,
their interrelationship should be investigated.
Both the current American College of Rheumatology
(ACR) recommendations and the European League
Against Rheumatism guidelines recommend methotrexate
(MTX) as first-line therapy for RA, with the addition of bio-
logic disease-modifying antirheumatic drugs (DMARDs) in
patients who experience an inadequate response to MTX
(2,3). Abatacept is a T-cell costimulation modulator that
has shown efficacy in patients with RA in a wide range of
disease and treatment durations (4–11). The AMPLE (Aba-
tacept versus Adalimumab Comparison in Biologic-Naive
RA Subjects with Background MTX) trial, the first head-to-
head trial comparing biologic DMARDs in patients with RA
receiving MTX, demonstrated noninferiority for abatacept
versus adalimumab by the ACR 20% improvement
response (ACR20) at year 1 (64.8% subcutaneous [SC] aba-
tacept versus 63.4% adalimumab; estimated difference
between treatments 1.8% [95% confidence interval (95%
CI) 25.6, 9.2] in an intent-to-treat analysis) (12). In AMPLE,
there was a similar time of onset of ACR20 response in
both treatment groups, with the response maintained up to
year 2 (13).
AMPLE included a diverse range of PRO analyses and is
the first biologic DMARD head-to-head evaluation of
PROs in RA. Comparable improvements from baseline to
year 1 were seen in fatigue with SC abatacept and adali-
mumab (223.2% SC abatacept versus 221.4% adalimu-
mab; adjusted treatment difference 21.8% [95% CI 25.8,
2.2]) (12). Results for pain over 1 and 2 years have also
been presented previously (14). Here, 2-year results from
the AMPLE trial are reported, directly comparing the
effects of abatacept and adalimumab on the PROs of pain,
fatigue, the ability to perform work, and the ability to per-
form daily activities, as well as the relationship between
these 4 PROs and clinical outcomes.
PATIENTS AND METHODS
The AMPLE study design and patient inclusion/exclusion
criteria have been described previously (13). Briefly,
patients had active RA for #5 years, as defined by the
1987 ACR criteria for RA (15), had reported an inadequate
response to MTX, were biologics-naive, and had a Disease
Activity Score in 28 joints using the C-reactive protein
(DAS28-CRP) level $3.2. Patients were randomly assigned
(1:1) to either SC abatacept (125 mg/week) or adalimumab
(40 mg every 2 weeks), in addition to a stable dose of MTX
(15–25 mg/week).
This study was conducted in accordance with the ethi-
cal principles of the Declaration of Helsinki; with Good
Clinical Practice, as defined by the International Confer-
ence on Harmonization; with the ethical principles under-
lying European Union Directive 2001/20/EC; and with the
US Code of Federal Regulations, Title 21, Part 50
(21CFR50). The laws and regulatory requirements of all
countries participating in this study were followed.
PRO assessments. PROs deemed important to patients
with RA and assessed in AMPLE were pain, fatigue, abili-
ty to perform work, and ability to perform daily activities.
All except pain were evaluated on day 1, month 6, year 1,
and year 2.
Pain and fatigue. Pain was measured using a 100-mm
visual analog scale (VAS), with a minimum clinically
important difference (MCID) defined as a change of
210 mm from baseline (14,16). Pain was evaluated at days
1, 15, and 29, and every 4 weeks thereafter during year 1,
and every 3 months during year 2. Patients’ assessment of
the severity of fatigue over the past week was measured
using a 100-mm VAS. An MCID was defined as a change
of 210 mm from baseline (17).
Ability to perform work. Four components of the Work
Productivity and Activity Impairment Questionnaire:
Rheumatoid Arthritis (WPAI:RA) were analyzed, includ-
ing absenteeism (work time missed), presenteeism
(impairment at work/reduced on-the-job effectiveness),
work productivity loss (overall work impairment/absen-
teeism plus presenteeism), and activity impairment. For
baseline values these components are reported as work
time missed, impairment at work, overall work impair-
ment, and activity impairment. For posttreatment values
they are reported as work time gained, reduced impair-
ment while working, overall reduced work impairment,
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and activity gained. An MCID for WPAI:RA was defined
as a 7% absolute change in WPAI:RA score (18).
Ability to perform daily activities. The Activity Limita-
tion Questionnaire was used to assess the number of days
in the past 30 days that a patient was unable (baseline val-
ues) or able (posttreatment values) to perform usual activi-
ties owing to RA. An MCID was defined as a change of 4
days from baseline (i.e., patients able to perform daily
activities on 4 additional days) (17).
Post hoc analyses: PROs in clinical responders versus
nonresponders. Post hoc analyses were performed to
determine the proportions of patients who achieved clini-
cal response scores according to the following criteria:
ACR20 response, Clinical Disease Activity Index (CDAI)
low disease activity (,10) and remission (,2.8), Simplified
Disease Activity Index (SDAI) low disease activity (,11)
and remission (,3.3), and Boolean remission (,1). The 4
PROs (pain, fatigue, ability to perform work, and ability to
perform daily activities) were compared for patients with
clinical responses (responders, as defined above) and those
without (nonresponders) at month 6, year 1, and year 2.
Statistical analysis. All efficacy analyses were per-
formed on the intent-to-treat population, which included
all patients who were randomized and received $1 dose
of study drug. Baseline demographics and clinical charac-
teristics were analyzed descriptively. For fatigue and abil-
ity to perform daily activities, changes from baseline were
summarized by treatment and visit, and 95% CIs for the
treatment differences were constructed. For ability to per-
form work, percentage reduction from baseline in each of
the 4 components of impairment was reported by treat-
ment and visit. Between–treatment group differences in
impairment reduction were also assessed using the point
estimation and 95% CI. Definitions of MCIDs for individu-
al outcomes are given above. For all patients who complet-
ed day 729 (year 2), individual responses/nonresponses
for ACR20 response and remission/low disease activity
(CDAI, SDAI, and Boolean) were calculated using post
hoc analyses of as-observed data (i.e., all data available).
All patients who prematurely discontinued the study after
receiving study drug, regardless of reason, were consid-
ered nonresponders at all subsequent visits for the clinical
response measures. For all PROs, adjusted mean changes
from baseline were summarized by treatment group and
were based on an analysis of covariance model, with treat-
ment as the main factor and baseline values with DAS28-
CRP stratification as covariates.
RESULTS
A total of 646 patients were randomized and treated, 318
patients in the SC abatacept group and 328 patients in the
adalimumab group. Demographic and baseline clinical char-
acteristics, including PRO measures, were well balanced
between the 2 treatment groups (Table 1). Overall, 79.2% of
patients treated with SC abatacept and 74.7% of patients
treated with adalimumab completed the 2-year study.
Change in PROs during the study period. Pain. Over
the 2-year study period, comparable improvements were
seen in the SC abatacept and adalimumab treatment
Table 1. Baseline demographics and patient-reported outcomes*
Demographics and PROs




Age, years 51.4 6 12.6 51.0 6 12.8
Women, % 81.4 82.3
White, % 80.8 78.0
Disease duration, years 1.9 6 1.4 1.8 6 1.4
HAQ DI score 1.5 6 0.7 1.5 6 0.7
DAS28-CRP score 5.5 6 1.1 5.5 6 1.1
Pain score† 63.1 6 22.3 65.5 6 21.8
Fatigue score† 60.6 6 25.0 60.1 6 25.4
Ability to perform work score‡
Percentage work time missed 10.9 6 21.5 13.5 6 25.1
Percentage impairment at work 47.2 6 28.5 51.4 6 27.7
Percentage overall work impairment 50.2 6 29.5 54.4 6 29.6
Percentage activity impairment 56.3 6 24.6 57.1 6 25.9
Ability to perform daily activities score, days§ 11.7 6 10.4 12.4 6 10.3
* Values are mean 6 SD unless indicated otherwise. Baseline fatigue, ability to perform work, and ability to
perform daily activities scores presented for patients with available data at 2 years (abatacept and adalimu-
mab, respectively: fatigue, n 5 310 and n 5 315; work time missed, n 5 137 and n 5 130; impairment at work,
overall work impairment, and activity impairment, n 5 134 and n 5 126; ability to perform daily activities,
n 5 308 and n 5 310). SC 5 subcutaneous; MTX 5 methotrexate; HAQ DI 5 Health Assessment Questionnaire
disability index; DAS28-CRP 5 Disease Activity Score in 28 joints using the C-reactive protein level.
† Pain and fatigue measured on a visual analog scale with 100-mm score.
‡ Ability to perform work assessed using the Work Productivity and Activity Impairment Questionnaire:
Rheumatoid Arthritis.
§ Ability to perform daily activities assessed as the number of days that patients were unable to perform nor-
mal activities during the past 30 days using the Activity Limitation Questionnaire.
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groups for most of the 4 PROs assessed. Numerically great-
er improvements in pain were observed for patients who
received abatacept versus adalimumab over 2 years (14).
Mean 6 SEM improvements in pain at year 2 for abatacept
versus adalimumab were 53.7% 6 6.2% versus 38.5% 6
6.1%, respectively, with an adjusted mean treatment dif-
ference of 15.2% (95% CI 21.2, 31.6) (published previous-
ly) (14). An MCID in pain was reached from day 15 for
both treatment groups.
Fatigue. Comparable improvements in fatigue were
observed in the abatacept and adalimumab treatment
groups over 2 years (Figure 1). Adjusted mean change in
fatigue reached an MCID (210 mm) as early as day 15 in
both treatment groups, with improvements being main-
tained up to year 2.
Ability to perform work. The 4 components of the
WPAI:RA were found to be similarly improved in patients
receiving abatacept and those receiving adalimumab over
the 2-year study (Figure 2). In both the abatacept and the
adalimumab treatment groups, improvements in the com-
ponents of reduced impairment while working, overall
reduced work impairment, and activity gained reached an
MCID (7%) at all postbaseline assessments (month 6, year
1, and year 2).
Ability to perform daily activities. As seen for the abili-
ty to perform work assessments, improvements in
patients’ ability to perform daily activities over 2 years
were similar in both the abatacept and the adalimumab
treatment groups (Figure 3). Again, the MCID for ability to
perform daily activities of 4 additional days was seen in
both treatment groups at all postbaseline assessments
(month 6, year 1, and year 2).
PROs in clinical responders versus nonrespon-
ders. The results of the post hoc analyses showed that, for
each of the 4 PROs evaluated, there was clear separation
between patients who achieved clinical response (res-
ponders) and those who did not (nonresponders), regard-
less of whether they received abatacept or adalimumab.
This separation was true for each of the 6 clinical out-
comes assessed, except when using Boolean remission to
assess the ability to perform daily activities in clinical
responders versus nonresponders. As pain was assessed
more frequently than the other PROs, which were assessed
at month 6, year 1, and year 2, the association of pain
improvement with clinical response is shown in Figure 4
and Supplementary Figure 1 (available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.22763/abstract) as a representative
example. Adjusted mean improvements in pain reached
an MCID as early as day 15 in both responder and nonres-
ponder groups for all low disease activity and remission cri-
teria; these improvements were maintained up to year 2 (see
Figure 4 and Supplementary Figure 1). For each PRO
and each clinical measure, the number of patients was
similar in the 2 treatment groups, for both responder and
Figure 2. Mean improvements in patient ability to perform work, over 2 years, as assessed by
the Work Productivity and Activity Impairment Questionnaire: Rheumatoid Arthritis, in an
intent-to-treat population. All patients with baseline and postbaseline measurements were used
for this analysis. Error bars represent SEM. SC 5 subcutaneous; MCID 5 minimum clinically
important difference.
Figure 1. Mean improvements in patient fatigue over 2 years, in
an intent-to-treat population. All patients with baseline and post-
baseline measurements were used for this analysis. Error bars
represent SEM. VAS 5 visual analog scale; MCID 5 minimum
clinically important difference; SC 5 subcutaneous.
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nonresponder subgroups. Abatacept and adalimumab res-
ponders had similar improvements in each PRO over time.
DISCUSSION
Over 2 years of the AMPLE trial, patients treated with SC
abatacept or adalimumab while receiving background
MTX achieved comparable, clinically meaningful
improvements with a similar onset of response in 4 PROs:
pain (14), fatigue, ability to perform work, and ability to
perform daily activities. Furthermore, post hoc analysis of
the 4 PROs showed a clear association between clinical
response according to several clinical criteria (ACR20
response, CDAI low disease activity, CDAI remission,
SDAI low disease activity, SDAI remission, and Boolean
remission) and improvement in PROs, with the exception
of an association between Boolean remission and the abili-
ty to perform daily activities.
PROs capture the effects of treatment from a patient’s
perspective and are critical to ensuring that a clinical
response corresponds to benefits that are perceptible and
important to the patient (19). Patients and clinicians want
RA treatments that rapidly improve health-related quality
of life and reduce or halt functional impairment, with
improvements maintained over time (20). Pain and loss of
physical function are meaningful outcomes that need to
be considered by clinicians as important consequences of
RA (21); patients also identify fatigue as having a consid-
erable influence on quality of life (22,23).
The results reported here are consistent with data from
other published studies of the effect of abatacept on PROs,
including ATTEST (Abatacept or Infliximab Versus Place-
bo: A Trial for Tolerability, Efficacy, and Safety in Treating
RA), AIM (Abatacept in Inadequate Responders to MTX),
and ACQUIRE (Abatacept Comparison of SC Versus Intrave-
nous in Inadequate Responders to MTX). As in AMPLE,
these 3 abatacept studies included patients with an inade-
quate response to MTX who were biologics-naive (5,24–26).
The results presented here are also consistent with pub-
lished PRO data for adalimumab (27–29). In the Anti-TNF
Research Study Program of the Monoclonal Antibody
Adalimumab trial, patients who had an inadequate
response to MTX and were treated with adalimumab plus
MTX demonstrated significant improvements in physical
function from baseline to year 4 (mean Health Assessment
Questionnaire disability index [HAQ DI] 0.7 and 1.5,
respectively [P , 0.001]) (27). Similarly, in the DE019 ada-
limumab study, patients who had an inadequate response
to MTX who received up to 10 years of adalimumab plus




Figure 4. Improvements in patient pain over 2 years in respond-
er and nonresponder patient subgroups, in an intent-to-treat
population, defined by clinical response criteria: (A) American
College of Rheumatology 20% improvement (ACR20) response,
(B) Simplified Disease Activity Index (SDAI) low disease activity
(LDA), and (C) SDAI remission. All patients with baseline and
postbaseline measurements were used for this analysis. Error bars
represent SEM. SC 5 subcutaneous; VAS 5 visual analog scale.
Figure 3. Mean improvements in patients’ activity limitation,
over 2 years, as number of days that patients are able to perform
normal activities during the past 30 days, assessed by the Activ-
ity Limitation Questionnaire in an intent-to-treat population. All
patients with baseline and postbaseline measurements were used
for this analysis. Error bars represent SEM. SC 5 subcutaneous;
MCID 5 minimum clinically important difference.
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from 1.4 at baseline to 0.7 at year 10, while 42% of
patients achieved HAQ DI ,0.5 (normal functionality) at
year 10 (28). In the PREMIER study, significant improve-
ments from baseline to year 2 in HAQ DI (P , 0.0001),
Short Form 36 health survey physical component summa-
ry score (P , 0.0001), patient global assessment score (P ,
0.0001), and pain score (P , 0.0001) were reported by
patients with early RA treated with adalimumab plus
MTX versus patients treated with MTX monotherapy (29).
The goal of current treat-to-target strategies in patients
with RA is the achievement of remission, but with the recog-
nition that low disease activity may be an acceptable alter-
native if remission is not achievable, particularly for those
with advanced established disease (30). By correlating clini-
cal response with PROs that are important to both physi-
cians and patients, such as pain, fatigue, work productivity,
and activity impairment, the achievement of how a good
clinical response translates into meaningful benefits for the
patient in their daily life can be better understood. Greater
reductions in the signs and symptoms of RA (ACR20
response) and disease activity (low disease activity or remis-
sion, as assessed by SDAI, CDAI, or Boolean criteria) were
associated with greater improvements over 2 years in the 4
PROs assessed (except for ability to perform daily activities
when assessed by Boolean remission), with comparable ben-
efits observed with SC abatacept and adalimumab.
Concerning the effect of RA on the ability to maintain
employment, previous studies have found greater disease
activity to be significantly correlated with higher numbers
of missed work hours (absenteeism), greater work impair-
ment (presenteeism), and greater activity impairment
(31,32). How relatively small changes in disease activity,
such as from low disease activity to remission, can impact
PROs is unclear. Nonetheless, reaching an MCID in pain,
fatigue, or physical function can result in significantly
greater improvements in work productivity compared
with patients who did not achieve MCID in these out-
comes (33). Furthermore, a recent study reported worse
work productivity in patients achieving low disease activ-
ity than in those achieving disease remission (34).
Limitations to this analysis should be considered.
Although the AMPLE trial was powered to compare abata-
cept and adalimumab directly, it was a single-blind
design, rather than double-blind, which may have intro-
duced bias (14). An additional limitation was the post hoc
nature of the analyses that compared PROs in patient sub-
groups based on clinical response.
In summary, this study demonstrated that in patients
with RA who were biologics-naive, treatment with SC aba-
tacept or adalimumab is associated with comparable
improvements in PROs that are considered particularly
important in RA (pain, fatigue, work productivity, and
activity limitation). Furthermore, improved PROs were
associated with physician-reported clinical responses.
ACKNOWLEDGMENT
Professional medical writing and editorial assistance
were provided by Carolyn Tubby, PhD (Caudex), and
funded by Bristol-Myers Squibb.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors
approved the final version to be submitted for publication. Dr.
Fleischmann had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy
of the data analysis.
Study conception and design. Fleischmann, Weinblatt, Schiff,
Khanna, Maldonado, Nadkarni, Furst.
Acquisition of data. Fleischmann, Furst.
Analysis and interpretation of data. Fleischmann, Weinblatt,
Schiff, Khanna, Nadkarni, Furst.
ROLE OF THE STUDY SPONSOR
Bristol-Myers Squibb facilitated the study design and reviewed
and approved the manuscript prior to submission. The authors
had full access to the study data, contributed to the interpretation
of the results, and had ultimate control over the decision to
publish and the final version of the manuscript submitted for
publication.
REFERENCES
1. Wells AF, Jodat N, Schiff M. A critical evaluation of the role
of subcutaneous abatacept in the treatment of rheumatoid
arthritis: patient considerations. Biologics 2014;8:41–55.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF,
Kremer JM, et al. 2012 update of the 2008 American College
of Rheumatology recommendations for the use of disease-
modifying antirheumatic drugs and biologic agents in the
treatment of rheumatoid arthritis. Arthritis Care Res (Hobo-
ken) 2012;64:625–39.
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P,
Gaujoux-Viala C, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and bio-
logical disease-modifying antirheumatic drugs. Ann Rheum
Dis 2010;69:964–75.
4. Westhovens R, Robles M, Ximenes AC, Nayiager S,
Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of
abatacept in methotrexate-naive patients with early rheuma-
toid arthritis and poor prognostic factors. Ann Rheum Dis
2009;68:1870–7.
5. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P,
Abud-Mendoza C, et al. Effects of abatacept in patients with
methotrexate-resistant active rheumatoid arthritis: a random-
ized trial. Ann Intern Med 2006;144:865–76.
6. Kremer JM, Russell AS, Emery P, Abud-Mendoza C,
Szechinski J, Westhovens R, et al. Long-term safety, efficacy
and inhibition of radiographic progression with abatacept
treatment in patients with rheumatoid arthritis and an inad-
equate response to methotrexate: 3-year results from the
AIM trial. Ann Rheum Dis 2011;70:1826–30.
7. Smolen J, Dougados M, Gaillez C, Poncet C, Le Bars M,
Mody M, et al. Remission according to different composite
disease activity indices in biologic-naive patients with rheu-
matoid arthritis treated with abatacept or infliximab plus
methotrexate. Arthritis Rheum 2011;63 Suppl:S477.
8. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC,
Keystone E. Safety of the selective costimulation modulator
abatacept in rheumatoid arthritis patients receiving back-
ground biologic and nonbiologic disease-modifying anti-
rheumatic drugs: a one-year randomized, placebo-controlled
study. Arthritis Rheum 2006;54:2807–16.
9. Westhovens R, Kremer JM, Emery P, Russell AS, Li T,
Aranda R, et al. Consistent safety and sustained improve-
ment in disease activity and treatment response over 7 years
of abatacept treatment in biologic-na€ıve patients with RA.
Ann Rheum Dis 2009;68 Suppl 3:577.
912 Fleischmann et al
10. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y,
Kremer J, et al. Abatacept for rheumatoid arthritis refractory
to tumor necrosis factor alpha inhibition. N Engl J Med
2005;353:1114–23.
11. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V,
Durez P, Zhou X, et al. The 6-month safety and efficacy of
abatacept in patients with rheumatoid arthritis who under-
went a washout after anti-tumour necrosis factor therapy or
were directly switched to abatacept: the ARRIVE trial. Ann
Rheum Dis 2009;68:1708–14.
12. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G,
Zhao C, et al. Head-to-head comparison of subcutaneous
abatacept versus adalimumab for rheumatoid arthritis: find-
ings of a phase IIIb, multinational, prospective, randomized
study. Arthritis Rheum 2013;65:28–38.
13. Schiff M, Weinblatt M, Valente R, van der Heijde D, Citera G,
Elegbe A, et al. Head-to-head comparison of subcutaneous
abatacept versus adalimumab on background methotrexate in
RA: two year results from the AMPLE study. Ann Rheum Dis
2013;72 Suppl 3:64.
14. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G,
Elegbe A, et al. Head-to-head comparison of subcutaneous aba-
tacept versus adalimumab for rheumatoid arthritis: two-year
efficacy and safety findings from AMPLE trial. Ann Rheum Dis
2014;73:86–94.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid
arthritis. Arthritis Rheum 1988;31:315–24.
16. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS,
Farrar JT, et al. Interpreting the clinical importance of treat-
ment outcomes in chronic pain clinical trials: IMMPACT
recommendations. J Pain 2008;9:105–21.
17. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Determin-
ing the minimal clinically important differences in activity,
fatigue, and sleep quality in patients with rheumatoid arth-
ritis. J Rheumatol 2007;34:280–9.
18. Reilly MC, Brown MC, Brahant Y, Gerlier L, Tan SC,
Sandborn WJ. Defining the minimally important difference
for WPAI. CD scores: what is a relevant impact on work pro-
ductivity in active Crohn’s disease. Gut 2007;56 Suppl 3:
159.
19. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Respon-
siveness of patient reported outcomes including fatigue,
sleep quality, activity limitation, and quality of life follow-
ing treatment with abatacept for rheumatoid arthritis. Ann
Rheum Dis 2008;67:260–5.
20. Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK,
Tugwell PS, et al. It’s good to feel better but it’s better to
feel good and even better to feel good as soon as possible
for as long as possible: response criteria and the importance
of change at OMERACT 10. J Rheumatol 2011;38:1720–7.
21. Pollard L, Choy EH, Scott DL. The consequences of rheuma-
toid arthritis: quality of life measures in the individual
patient. Clin Exp Rheumatol 2005;23:S43–52.
22. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M,
Hehir M, et al. Incorporating the patient perspective into
outcome assessment in rheumatoid arthritis: progress at
OMERACT 7. J Rheumatol 2005;32:2250–6.
23. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA.
Impact of fatigue on health-related quality of life in rheumatoid
arthritis. Arthritis Rheum 2004;51:578–85.
24. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A,
Nayiager S, et al. Efficacy and safety of abatacept or infliximab
vs placebo in ATTEST: a phase III, multi-centre, randomised,
double-blind, placebo-controlled study in patients with rheu-
matoid arthritis and an inadequate response to methotrexate.
Ann Rheum Dis 2008;67:1096–103.
25. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P,
Abud-Mendoza C, et al. Results of a two-year followup
study of patients with rheumatoid arthritis who received a
combination of abatacept and methotrexate. Arthritis Rheum
2008;58:953–63.
26. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M,
Valente R, et al. Subcutaneous abatacept versus intravenous
abatacept: a phase IIIb noninferiority study in patients with an
inadequate response to methotrexate. Arthritis Rheum 2011;63:
2854–64.
27. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF,
Chartash EK, Segurado OG. Long term efficacy and safety of
adalimumab plus methotrexate in patients with rheumatoid
arthritis: ARMADA 4 year extended study. Ann Rheum Dis
2006;65:753–9.
28. Keystone EC, van der Heijde D, Kavanaugh A, Kupper H,
Liu S, Guerette B, et al. Clinical, functional, and radiographic
benefits of longterm adalimumab plus methotrexate: final 10-
year data in longstanding rheumatoid arthritis. J Rheumatol
2013;40:1487–97.
29. Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D.
Health-related quality of life outcomes of adalimumab for
patients with early rheumatoid arthritis: results from a ran-
domized multicenter study. J Rheumatol 2012;39:63–72.
30. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas
D, Burmester G, et al. Treating rheumatoid arthritis to target:
recommendations of an international task force. Ann Rheum
Dis 2010;69:631–7.
31. Chaparro del Moral R, Rillo OL, Casalla L, Moron CB, Citera
G, Cocco JA, et al. Work productivity in rheumatoid arth-
ritis: relationship with clinical and radiological features.
Arthritis 2012;2012:137635.
32. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis
AH. Validity of the work productivity and activity impair-
ment questionnaire: general health version in patients with
rheumatoid arthritis. Arthritis Res Ther 2010;12:R177.
33. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P.
Physical function improvements and relief from fatigue and
pain are associated with increased productivity at work and
at home in rheumatoid arthritis patients treated with certoli-
zumab pegol. Rheumatology (Oxford) 2010;49:1900–10.
34. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid
arthritis: benefit over low disease activity in patient-
reported outcomes and costs. Arthritis Res Ther 2014;16:
R56.
2-Year Patient-Reported Outcomes: Abatacept Versus Adalimumab 913
